Steve Harris, chief executive of PLC (), talks Proactive London's Andrew Scott through the group's 2018 results and the first quarter of this year.
Circassia's taken full commercial control of Tudorza, a treatment for chronic obstructive pulmonary disease (COPD), while its sales of its asthma product NIOX continued to grow.
They've also added AirNOvent, a late-stage nitric oxide candidate, to its pipeline, which, when approved, should aid the sales effort.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Circassia Pharmaceuticals PLC named herein, including the promotion by the Company of Circassia Pharmaceuticals PLC in any Content on the Site,...
FOR OUR FULL DISCLAIMER CLICK HERE